Everest Medicines (HKSE:01952) FCF Margin %: -15.64% (As of Dec. 2025)


HKSE:01952 Everest Medicines Ltd HKSE:01952
43 GF Score
Price HK$27.80
GF Value HK$290.08
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Everest Medicines FCF Margin %?

Everest Medicines HKSE:01952 +8.68% 43 FCF Margin % is -15.64% as of Dec. 2025. GuruFocus rates HKSE:01952 with a GF Score™ of 43/100 and a GF Value™ of HK$290.08 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 954 Biotechnology companies, Everest Medicines ranks better than 61.43% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Everest Medicines's Free Cash Flow for the six months ended in Dec. 2025 was HK$-218 Mil. Everest Medicines's Revenue for the six months ended in Dec. 2025 was HK$1,393 Mil. Therefore, Everest Medicines's FCF Margin % for the quarter that ended in Dec. 2025 was -15.64%.

As of today, Everest Medicines's current FCF Yield % is -4.96%.

The historical rank and industry rank for Everest Medicines's FCF Margin % or its related term are showing as below:

HKSE:01952' s FCF Margin % Range Over the Past 10 Years
Min: -3164603.03   Med: -821.98   Max: -25.75
Current: -25.75

During the past 8 years, the highest FCF Margin % of Everest Medicines was -25.75%. The lowest was -3164603.03%. And the median was -821.98%.

HKSE:01952's FCF Margin % is ranked better than
61.43% of 954 companies
in the Biotechnology industry
Industry Median: -84.535 vs HKSE:01952: -25.75

Everest Medicines FCF Margin % Related Terms

Everest Medicines FCF Margin % Historical Data

* Premium members only.

The historical data trend for Everest Medicines's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines FCF Margin % Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -3,164,603.03 -12,417.96 -821.98 -125.04 -25.83

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -387.17 -170.22 -91.43 -54.65 -15.64

HKSE:01952 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Everest Medicines's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's FCF Margin % falls into.


HKSE:01952
43GF Score
Everest Medicines Ltd HKSE:01952
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Everest Medicines FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Everest Medicines's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-487.076/1885.41
=-25.83 %

Everest Medicines's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-217.733/1392.567
=-15.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -15.64% mean?
Everest Medicines (HKSE:01952) has a FCF Margin % of -15.64% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Everest Medicines and its competitors. According to the industry distribution chart, Everest Medicines ranks #368 out of 954 companies in the Biotechnology industry, placing it in the top 38.6%.
Is Everest Medicines' FCF Margin % too high?
Everest Medicines' current FCF Margin % is -15.64%. Based on the distribution chart, Everest Medicines ranks #368 out of 954 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Everest Medicines has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #368 out of 954 companies for FCF Margin %. This puts Everest Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Everest Medicines and its competitors. Everest Medicines's current FCF Margin % is -15.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Possible Value Trap. The stock's GF Value™ is HK$290.08, compared to a current price of HK$27.80 — trading 90.4% below its estimated fair value. The current FCF Margin % is -15.64%. Everest Medicines' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current FCF Margin % is -15.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Everest Medicines (HKSE:01952) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of HK$27.80 is trading 90.4% below its estimated GF Value™ of HK$290.08. GuruFocus considers Everest Medicines to be Possible Value Trap.

Key valuation signals for HKSE:01952:

  • FCF Margin %: -15.64%
  • GF Value™: HK$290.08 vs. price of HK$27.80 (90.4% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 6HN:Germany
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
43GF Score

Get the complete analysis for HKSE:01952

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.80
Price
HK$290.08
GF Value